Search

Huawei Qiu

from Westborough, MA
Age ~62
Get Report
Also known as:
Hua Wei Qiu, Hua W Qiu, Huawei Qui, Hua-Wei Qiu, Wei Qiu Hua, Qui Huawei, Qiu Hua-Wei
Phone and address:
5 Primrose Ln, Westboro, MA 01581
(508) 366-0665
Connected to:
Angel Qiu, 26Biao Qiu, 39Cheng F Qiu, 50Christine N Qiu, 37Cui F Qiu, 46Guo Q Qiu, 65Guosheng Qiu, 56Haichun Qiu, 50Hong QiuJames Qiu, 46

Huawei Qiu Phones & Addresses

  • 5 Primrose Ln, Westborough, MA 01581 (508) 366-0665
  • 5 Valley Brook Rd, Westborough, MA 01581 (508) 366-0665
  • Westboro, MA
  • 154 Gerry Rd, Chestnut Hill, MA 02467 (617) 469-8368
  • 214 Gerry Rd, Chestnut Hill, MA 02467 (617) 469-8368
  • Boston, MA
  • Providence, RI
  • College Station, TX

Work

Company: Xilio therapeutics, inc. Apr 2019 Position: Vice president, biologics

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Texas A&M University 1988 to 1994 Specialities: Biochemistry, Philosophy

Skills

Biotechnology • Protein Chemistry • Drug Discovery • Molecular Biology • Protein Engineering • Antibodies • Biochemistry • Antibody Engineering • Life Sciences • Drug Development

Industries

Biotechnology

Resumes

Resumes

Huawei Qiu Photo 1

Vice President, Biologics

View page
Location:
Boston, MA
Industry:
Biotechnology
Work:
Xilio Therapeutics, Inc.
Vice President, Biologics
Sanofi Apr 2013 - Mar 2019
Director To Senior Director, Head of Protein Engineering, Biologics Research
Sanofi Genzyme May 1999 - Apr 2011
Scientist To Associate Director, Therapeutic Protein Research and Protein Engineering
Brigham and Women's Hospital Jul 1995 - Apr 1999
Postdoctoral Fellow
Brown University May 1994 - Jun 1995
Postdoctoral Fellow
Education:
Texas A&M University 1988 - 1994
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy Peking University
Bachelors, Bachelor of Science, Chemistry
Skills:
Biotechnology
Protein Chemistry
Drug Discovery
Molecular Biology
Protein Engineering
Antibodies
Biochemistry
Antibody Engineering
Life Sciences
Drug Development

Publications

Us Patents

Modified Human Acid Spingomyelinase Having Increased Activity, And Methods For Making The Same

View page
US Patent:
20050169906, Aug 4, 2005
Filed:
Jun 10, 2004
Appl. No.:
10/864981
Inventors:
Scott Van Patten - Ashland MA, US
Kenneth Karey - Bolton MA, US
Huawei Qiu - Westborough MA, US
Assignee:
Genzyme Corporation - Cambridge MA
International Classification:
A61K038/46
C07H021/04
C12N009/10
C12N009/20
C12N015/85
US Classification:
424094600, 435069100, 435455000, 435198000, 435325000, 536023200
Abstract:
Deficiencies in the enzymatic activity of acid sphingomyelinase (ASM) result in Niemann-Pick disease. A variety of modifications which eliminate the activity of the free thiol on the C-terminal cysteine residue of ASM all result in substantially increased specific activity of the enzyme. Methods used to alter the activity of this residue include site-directed mutagenesis to delete or alter the residue, enzymatic degradation of the ASM to remove the residue, copper-promoted dimerization of ASM (via the terminal cysteine residues) and chemical modification of the free thiol group on this residue.

Fusion Proteins Containing Two Tgf-Beta Binding Domains Of Tgf-Beta Type Ii Receptor

View page
US Patent:
20100204104, Aug 12, 2010
Filed:
Dec 24, 2008
Appl. No.:
12/663638
Inventors:
Huawei Qiu - Westborough MA, US
Steven R. Ledbetter - Westborough MA, US
Sirkka Kyostio-Moore - Ashland MA, US
International Classification:
A61K 38/16
C07K 14/00
C07H 21/04
C12N 15/63
C12N 5/10
C12P 21/06
A61P 13/12
A61K 31/7088
A61P 35/04
A61P 9/10
US Classification:
514 12, 530350, 536 234, 4353201, 435325, 435358, 435 697, 514 44 R
Abstract:
The disclosure provides fusion proteins that contain two TGF-β binding domains of TGF-β type II receptor joined to each other by a linker. For example, the C terminus of the first TGF-β binding domain is joined by a short peptide linker (e.g., a 9-glycine linker) to the N terminus of the second TGF-β binding domain. Despite the proximity of the C terminus of the first domain to N terminus of the second domain, such a fusion protein effectively neutralizes TGF-β, in some cases, similarly to anti-TGF-β antibodies.

Vegf Antagonist Compositions And Uses Thereof

View page
US Patent:
20130324465, Dec 5, 2013
Filed:
Aug 5, 2011
Appl. No.:
13/814182
Inventors:
James Stefano - Hopkinton MA, US
Clark Pan - Framingham MA, US
Huawei Qiu - Framingham MA, US
Michael O'Callaghan - Framingham MA, US
Gloria Matthews - Framingham MA, US
Assignee:
Genzyem Corporation - Westborough MA
International Classification:
C07K 14/71
C12N 9/12
US Classification:
514 81, 530350, 530410, 4353201, 435 691, 435369
Abstract:
The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.

Masked Cytokine Polypeptides

View page
US Patent:
20220306716, Sep 29, 2022
Filed:
Apr 8, 2022
Appl. No.:
17/716873
Inventors:
- Waltham MA, US
Deborah Moore LAI - Beverly MA, US
Dheeraj TOMAR - Dorchester MA, US
Parker JOHNSON - Allston MA, US
Raphael ROZENFELD - Newton MA, US
Ronan O'HAGAN - Waltham MA, US
Huawei QIU - Westborough MA, US
Assignee:
Xilio Development, Inc. - Waltham MA
International Classification:
C07K 14/55
A61P 35/00
C07K 14/54
Abstract:
Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.

Anti-Tgf-Beta Antibodies And Their Use

View page
US Patent:
20220195026, Jun 23, 2022
Filed:
Dec 23, 2021
Appl. No.:
17/561510
Inventors:
- Paris, FR
Kevin Brower - Holliston MA, US
Patrick Finn - Franklin MA, US
Richard C. Gregory - Framingham MA, US
Rao Koduri - Shrewsbury MA, US
Feng Liu - San Diego CA, US
Natalia Malkova - Needham MA, US
Parminder Mankoo - Foster City CA, US
Jack R. Pollard - Acton MA, US
Huawei Qiu - Westborough MA, US
Joachim Theilhaber - Cambridge MA, US
Christopher Winter - Swampscott MA, US
Marcella Yu - Fremont CA, US
Assignee:
SANOFI - Paris
International Classification:
C07K 16/22
A61P 35/00
C07K 16/28
C07K 16/30
C07K 16/32
Abstract:
The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

Thyroid Stimulating Hormone Compositions

View page
US Patent:
20230126645, Apr 27, 2023
Filed:
May 23, 2022
Appl. No.:
17/751433
Inventors:
- Cambridge MA, US
Huawei QIU - Westborough MA, US
Sunghae PARK - Waban MA, US
Assignee:
GENZYME CORPORATION - Cambridge MA
International Classification:
A61K 47/60
A61K 38/24
Abstract:
Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH. Also described are compositions of mutated Thyroid Stimulating Hormone (TSH) and at least one polyalkylene glycol polymer, wherein the mutated TSH comprises a TSH in which one or more amino acid residues has been substituted with cysteine residue, and the polyalkylene glycol polymer is attached to the mutated TSH at the site of the substituted cysteine residue. Pharmaceutical compositions comprising these TSH compositions and method of treating a thyroid condition in a patient in need thereof, by administering to the patient an effective amount of the pharmaceutical compositions are also described.

Tumor-Specific Cleavable Linkers

View page
US Patent:
20230072822, Mar 9, 2023
Filed:
Nov 24, 2021
Appl. No.:
17/535451
Inventors:
- Waltham MA, US
Ugur ESKIOCAK - Somerville MA, US
Huawei QIU - Westborough MA, US
Parker JOHNSON - Allston MA, US
Kurt Allen JENKINS - Weymouth MA, US
Dheeraj Singh TOMAR - Dorchester MA, US
Rebekah Kay O'DONNELL - Brookline MA, US
International Classification:
A61K 47/65
A61K 38/20
A61K 47/64
A61P 35/00
Abstract:
The present disclosure provides tumor-specific cleavable linkers and their use in drugs and prodrugs for delivering therapeutics to a tumor cell environment. The present disclosure also provides cleavage products of said drugs and prodrugs, and methods related to the use of the same.

Masked Cytokine Polypeptides

View page
US Patent:
20230030037, Feb 2, 2023
Filed:
Jun 4, 2021
Appl. No.:
17/339801
Inventors:
- Waltham MA, US
Deborah Moore LAI - Beverly MA, US
Dheeraj Singh TOMAR - Dorchester MA, US
Parker JOHNSON - Allston MA, US
Raphael ROZENFELD - Newton MA, US
Ronan O'HAGAN - Waltham MA, US
Huawei QIU - Westborough MA, US
Assignee:
Xilio Development, Inc. - Waltham MA
International Classification:
C07K 14/55
A61P 35/00
Abstract:
Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
Control profile
Huawei Qiu from Westborough, MA, age ~62 Get Report